JPH07147934A - Lipid increase inhibitor - Google Patents
Lipid increase inhibitorInfo
- Publication number
- JPH07147934A JPH07147934A JP5321138A JP32113893A JPH07147934A JP H07147934 A JPH07147934 A JP H07147934A JP 5321138 A JP5321138 A JP 5321138A JP 32113893 A JP32113893 A JP 32113893A JP H07147934 A JPH07147934 A JP H07147934A
- Authority
- JP
- Japan
- Prior art keywords
- xyloglucan
- decomposition
- degradation product
- lipid
- increase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明はキシログルカン分解物を
有効成分とする脂質増加抑制剤に関する。TECHNICAL FIELD The present invention relates to a lipid increase inhibitor containing a xyloglucan degradation product as an active ingredient.
【０００２】[0002]
【従来の技術および発明が解決しようとする課題】近
年、我が国を含め先進工業化諸国では”豊かさ”の産物
であるエネルギ−と脂質の過剰摂取が、肥満，高脂血
症，糖尿病および高血圧症などの重大な疾患の原因の１
つとされ、健康上大きな問題となっている。さらに、肥
満，高脂血症は心臓循環系疾患の危険因子であり、ま
た、痛風，胆石症および肝臓病などにも強く関係してい
る。2. Description of the Related Art In recent years, in industrialized countries including Japan, excessive intake of energy and lipid, which are products of "abundance", causes obesity, hyperlipidemia, diabetes and hypertension. Cause of serious diseases such as
It has become a serious problem for health. Furthermore, obesity and hyperlipidemia are risk factors for cardiovascular diseases, and are also strongly associated with gout, gallstone disease, liver disease and the like.
【０００３】最近では、特に若い女性層の肥満への意識
は過敏であり、そのため、無理なダイエットを行い、栄
養バランスを崩すなどの問題が生じている。Recently, particularly among young women, the consciousness of obesity is hypersensitivity, which causes problems such as excessive dieting and upset nutritional balance.
【０００４】肥満，高脂血症の治療・予防の手段として
は、従来、食事量を制限する、食事内容を低カロリ−や
低脂肪のものに変えるなどして摂取カロリ−を低減させ
る、運動などして消費カロリ−を増やす、あるいは、薬
物や食品成分に由来する生理活性物質を摂取するなどで
あった。しかし、摂取カロリ−を減らしたり、消費カロ
リ−を増やしたりすることは長期にわたり快適な食生活
を損ない、また、適切な指導や堅固な意志が必要なので
実際にはかなり難しい。薬物の服用は副作用やコストに
問題がある。また、食品成分に由来する生理活性物質、
例えば、ペクチンやグア−ガムの天然多糖類（例えば、
桐山修八編「食物繊維」第一出版），培焼デキストリン
（特開平３−２４７２５８），分岐脂肪酸（特開平３−
２４７２５８），リパ−ゼインヒビタ−（特開平４−３
２７５３６）等の摂取は、摂取時の風味，食感が損なわ
れ、また、摂取しても有効性は低く、大量の摂取を必要
とし、ときには、緩下作用などの副作用が生ずる。しか
しながら、食品成分に由来する生理活性物質を摂取する
ことは簡便な手段であるので、特に、食品業界では、食
事とともに美味に摂取でき、しかも、肥満に対する予防
的な意味をもつ有効な素材が望まれている。As a means for treating / preventing obesity and hyperlipidemia, exercise has conventionally been carried out to reduce the calorie intake by limiting the amount of food, changing the content of the meal to a low-calorie or low-fat one, and the like. For example, the calorie consumption is increased, or the physiologically active substance derived from a drug or food ingredient is ingested. However, reducing the calorie intake and increasing the calorie consumption impairs a comfortable eating habit for a long period of time, and requires proper guidance and a strong will and is actually quite difficult. Taking drugs has side effects and costs. Also, physiologically active substances derived from food ingredients,
For example, natural polysaccharides such as pectin and guar gum (eg,
Kiriyama Shuhachi, "Dietary Fiber," First Publication), Baiyaki Dextrin (JP-A-3-247258), Branched fatty acid (JP-A-3-
247258), lipase inhibitor (JP-A-4-3)
Ingestion such as 27536) impairs the flavor and texture at the time of ingestion, is ineffective even if ingested, requires a large amount of intake, and sometimes causes side effects such as laxative action. However, since ingesting physiologically active substances derived from food ingredients is a simple means, in the food industry, in particular, an effective material that can be ingested deliciously with meals and that has a preventive meaning against obesity is desired. It is rare.
【０００５】従来、グア−ガム，ロ−カストビ−ンガ
ム，タラガムなどの、ガラクト−スとマンノ−スから構
成されるガラクトマンナンの酵素分解物に脂質低下作用
があることが知られている（特開平２−２２９１１７
号）。Conventionally, it has been known that enzymatic degradation products of galactomannan composed of galactose and mannose, such as guar gum, locust bean gum and tara gum, have a lipid-lowering action (special characteristics. Kaihei 2-229117
issue).
【０００６】また、コンニャクマンナン，グア−ガム，
キサンタンガムなどの高粘度多糖類を高圧ホモジナイザ
−で低粘性化（２００ｃｐｓ以下）した低粘度多糖類に
もコレステロ−ル値上昇抑制作用が保持されていること
は知られている（特公平４−２９６４６号）。Also, konjac mannan, guar gum,
It is known that a low-viscosity polysaccharide obtained by reducing the viscosity of a high-viscosity polysaccharide such as xanthan gum with a high-pressure homogenizer (200 cps or less) also has an inhibitory effect on cholesterol level increase (Japanese Patent Publication No. 4-29646). issue).
【０００７】一方、キシログルカンは双子葉，単子葉植
物など高等植物の生長している細胞壁（一次壁）に存在
する多糖であり、タマリンドをはじめ、大豆，緑豆，イ
ンゲンマメ，イネ，オオムギ，リンゴなどにも存在す
る。また、西洋カエデの１つであるシカモレ(Sycamore)
の細胞培養によっても得ることができる。[0007] On the other hand, xyloglucan is a polysaccharide present in the cell wall (primary wall) of higher plants such as dicotyledonous and monocotyledonous plants, and includes tamarind, soybean, mung bean, common bean, rice, barley, apple, etc. Also exists. Also, Sycamore, one of the Western maples
It can also be obtained by cell culture.
【０００８】キシログルカンはグルコ−スとキシロ−ス
を主な構成糖とする多糖類で、主鎖はグルコ−スがβ１
→４結合したものであり、側鎖は主にキシロ−スから成
り、タマリンド種子多糖類はその１例である。キシログ
ルカンを酸または酵素で分解すると分解物が得られる
が、分解条件によってはキシログルカンオリゴ糖が得ら
れる。[0008] Xyloglucan is a polysaccharide whose main constituent sugars are glucose and xylose, and the main chain of which is glucose is β1.
→ 4 linked, the side chain is mainly composed of xylose, and tamarind seed polysaccharide is one example. Decomposition products are obtained by decomposing xyloglucan with an acid or an enzyme, and xyloglucan oligosaccharides are obtained depending on the decomposition conditions.
【０００９】これまでに、キシログルカンオリゴ糖は植
物の成長に関与することが知られていた。例えば、５
糖，７糖，９糖のキシログルカンオリゴ糖が植物由来の
エンド−１，４−β−グルカナ−ゼを活性化すること
（ブイ・ファルカス等，カ−ボハイドレ−ト・リサ−チ
第１８４巻第２１３−２１９頁１９８８年）、また、７
糖，８糖，９糖のキシログルカンオリゴ糖がエンドウ胚
軸切片の伸長を促進すること（ゴ−ドン・ジェイ・マク
ドゴ−ル等，プラント・フィジオロジ−第９３巻第１０
４２−１０４８頁１９９０年）、さらに、９糖のキシロ
グルカンオリゴ糖がオ−キシンによる伸長の阻害作用を
有すること（ゴ−ドン・ジェイ・マクドゴ−ル等，プラ
ント・フィジオロジ−第８９巻第８８３−８８７頁１９
８９年）が知られている。Up to now, it has been known that xyloglucan oligosaccharide is involved in plant growth. For example, 5
Xyloglucan oligosaccharides of sugars, 7 sugars and 9 sugars activate plant-derived endo-1,4-β-glucanase (Buy Falcas et al., Carbohydrate Research Volume 184). Pp. 213-219, 1988), also 7
Xyloglucan oligosaccharides of sugars, octasaccharides, and 9 sugars promote the elongation of pea hypocotyl slices (Gordon Jay McDogall et al., Plant Physiology, Vol. 93, No. 10).
42-1048, 1990), and that xyloglucan oligosaccharides of 9 sugars have an inhibitory effect on elongation caused by auxin (Gordon Jay McDogall et al., Plant Physiology, Vol. 89, 883). -887 page 19
1989) is known.
【００１０】しかしながら、キシログルカンオリゴ糖に
体内の脂質代謝改善作用があることはこれまでに知られ
ていない。However, it has not been known so far that xyloglucan oligosaccharides have an effect of improving lipid metabolism in the body.
【００１１】[0011]
【課題を解決するための手段】本発明者は、食事ととも
に美味に摂取でき、しかも、肥満に対する予防的な意味
をもつ有効な素材を鋭意探索した結果、キシログルカン
分解物が体内の脂質代謝改善作用、即ち、体脂肪の増加
抑制作用および血液のみならず肝臓のトリグリセリド
値，コレステロ−ル値等の上昇抑制作用を有するので、
肥満・高脂血症の予防・治療剤として使用できることを
見いだし、本発明を完成した。Means for Solving the Problems The present inventor diligently searched for an effective material that can be deliciously taken with meals and has a preventive meaning against obesity, and as a result, a xyloglucan degradation product improves lipid metabolism in the body. Since it has an action, that is, an action of suppressing increase in body fat and an action of suppressing increase in triglyceride level, cholesterol level, etc. of the liver as well as blood,
They have found that they can be used as prophylactic / therapeutic agents for obesity / hyperlipidemia, and completed the present invention.
【００１２】本発明に用いられるキシログルカン分解物
の原料としてはいかなるキシログルカンでもよいが、キ
シログルカンの含有量が多く、入手も容易なタマリンド
種子由来のキシログルカン（タマリンド種子多糖類：商
品名「グリロイド」大日本製薬株式会社製）が好まし
い。The xyloglucan degradation product used in the present invention may be any xyloglucan, but xyloglucan derived from tamarind seeds (tamarind seed polysaccharide: trade name " Glyroid "manufactured by Dainippon Pharmaceutical Co., Ltd.) is preferable.
【００１３】タマリンド種子多糖類はβ−１，４−グル
カンからなる主鎖に、側鎖としてキシロ−ス，ガラクト
−スが結合した構造を有しており、食品用増粘剤として
ソ−ス，アイスクリ−ム等に繁用されている。Tamarind seed polysaccharide has a structure in which xylose and galactose are bonded as side chains to a main chain composed of β-1,4-glucan, and is used as a thickener for foods. , Is often used in ice cream.
【００１４】キシログルカンからキシログルカン分解物
を得る方法としては、従来から多糖類の解重合に用いら
れている手法、例えば、酵素分解，酸分解，アルカリ分
解，超音波による分解が挙げられる。これらの方法を用
いる場合、いずれの方法であってもよいが、温和な条件
で反応が進み、分子量の揃った分解物の得やすい酵素分
解が特に好ましい。As a method for obtaining a xyloglucan decomposition product from xyloglucan, there are methods conventionally used for depolymerization of polysaccharides, for example, enzymatic decomposition, acid decomposition, alkali decomposition, and ultrasonic decomposition. When any of these methods is used, any method may be used, but enzymatic decomposition is particularly preferable because the reaction proceeds under mild conditions and a decomposed product having a uniform molecular weight is easily obtained.
【００１５】キシログルカンの酵素分解に用いられる酵
素はβ−１，４−グルカナーゼ、即ち、所謂、セルラ−
ゼ活性を有する植物組織崩壊酵素であり、植物や微生物
から抽出・精製したものでも、市販の酵素製剤でも用い
ることができる。その際には、用いる酵素の特性に合わ
せた基質濃度，酵素濃度，ｐＨ，反応温度，反応時間で
分解すればよい。The enzyme used for the enzymatic decomposition of xyloglucan is β-1,4-glucanase, that is, so-called cellular.
It is a plant tissue-disintegrating enzyme having zease activity, and it can be used as an enzyme extracted and purified from plants or microorganisms, or as a commercially available enzyme preparation. In that case, it may be decomposed at a substrate concentration, an enzyme concentration, a pH, a reaction temperature, and a reaction time according to the characteristics of the enzyme used.
【００１６】キシログルカンを分解して得られた分解液
はそのまま、あるいは、樹脂処理やクロマトグラフィ−
等で精製して糖液として使用してもよいし、噴霧乾燥や
凍結乾燥などの方法で粉末化して用いてもよい。The decomposed liquid obtained by decomposing xyloglucan is used as it is, or is treated with resin or chromatographed.
And the like, and may be used as a sugar solution, or may be powdered by a method such as spray drying or freeze drying.
【００１７】上記のような方法で得られたキシログルカ
ン分解物は肥満・高脂血症の予防・治療剤として、単独
に、あるいは、様々な食品に添加して用いることができ
る。The xyloglucan degradation product obtained by the above method can be used alone or as a prophylactic / therapeutic agent for obesity / hyperlipidemia, or added to various foods.
【００１８】様々な食品の例としては、ジュ−ス類、乳
酸菌飲料、乳飲料、発酵乳、茶類（緑茶，紅茶，ウ−ロ
ン茶等）、冷菓（アイスクリ−ム，シャーベット等）、
ス−プ類、冷凍食品、粉末食品、シ−ト状食品、瓶詰食
品、缶詰食品、レトルト食品、漬物類、燻製品、干物、
佃煮、塩蔵品、畜肉製品（ハム，ソ−セ−ジ，ハンバ−
グ，ハンバ−ガ−パティ，ミ−トボ−ルなど）、魚肉練
り製品（蒲鉾，竹輪，さつま揚げなど）、乳製品（バタ
−，チ−ズ，ヨ−グルト，加工乳，脱脂乳など）、卵製
品（だし巻，卵豆腐など）、惣菜、パン類、菓子類（ケ
−キ，ゼリ−，プリン，シュ−クリ−ム，飴，スナック
菓子，饅頭など）、麺類（うどん，そば，中華麺，パス
タなど）、調味料（みそ，醤油，ソ−ス，ケチャップ，
たれ，マヨネ−ズなど）が挙げられる。Examples of various foods are juices, lactic acid beverages, milk drinks, fermented milk, teas (green tea, black tea, oolong tea, etc.), frozen desserts (ice cream, sherbet, etc.),
Soups, frozen foods, powdered foods, sheet foods, bottled foods, canned foods, retort foods, pickles, smoked products, dried foods,
Tsukudani, salted products, meat products (ham, sauce, hamburger)
Gu, hamburger patties, meatballs, etc.), fish paste products (kamaboko, bamboo rings, fried egg, etc.), dairy products (butter, cheese, yogurt, processed milk, skim milk, etc.), eggs Products (dashi rolls, egg tofu, etc.), side dishes, breads, confectionery (cake, jelly, pudding, cream, candy, snacks, buns, etc.), noodles (udon, soba, Chinese noodles, etc.) Pasta etc., seasonings (miso, soy sauce, sauce, ketchup,
Sauce, mayonnaise, etc.).
【００１９】後記製造例で製造されたキシログルカン分
解物を用いて、下記の試験例に従って脂質増加抑制作用
を調べた。Using the xyloglucan hydrolyzate produced in the production examples described later, the inhibitory effect on lipid increase was examined according to the following test examples.
【００２０】（試験例）ウィスタ−系雄性ラット（６週
令）を６匹ずつコントロ−ル群とテスト群の２群に分
け、各々の群に表１に示す配合の飼料（高脂肪食）を５
週間摂取させた（コントロ−ル群にはセルロ−スを、テ
スト群には製造例で得られたキシログルカン分解物を各
々５％添加した）。この間、飼料および飲料水は自由に
摂取させた。飼育期間終了後、一夜絶食させた。ネンブ
タ−ル麻酔下で腹部大動脈の血液を採取した後、肝臓を
摘出した。(Test Example) Male Wistar rats (6 weeks old) were divided into two groups, 6 groups each including a control group and a test group, and each group had a feed composition (high fat diet) having the composition shown in Table 1. 5
It was ingested for a week (cellose was added to the control group, and 5% of the xyloglucan degradation product obtained in the production example was added to the test group). During this time, feed and drinking water were freely available. After the breeding period, they were fasted overnight. Blood was collected from the abdominal aorta under Nembutal anesthesia, and then the liver was extracted.
【００２１】採取した血液は遠心分離（１１００ｇ，１
５分）にかけ、上清、即ち、血漿を得た。この血漿を自
動分析計（日立製作所製：日立−７３６）で測定し、各
血漿成分を求めた。脂肪組織の重量は、解剖し、腹腔内
の脂肪組織を取り出してその重量を測定して求めた。ま
た、飼料効率は体重増加量を飼料摂取量で除して求め
た。その結果を表２および表３に示す。The collected blood was centrifuged (1100 g, 1
5 minutes), the supernatant, that is, plasma was obtained. This plasma was measured with an automatic analyzer (Hitachi: Hitachi-736) to determine each plasma component. The weight of the adipose tissue was determined by dissecting the adipose tissue in the abdominal cavity and measuring the weight. The feed efficiency was calculated by dividing the weight gain by the feed intake. The results are shown in Tables 2 and 3.
【００２２】[0022]
【表１】 [Table 1]
【００２３】[0023]
【表２】 ＊＊ｐ＜０．０１[Table 2] ** p <0.01
【００２４】[0024]
【表３】 ＊ｐ＜０．０５[Table 3] * P <0.05
【００２５】表２から、キシログルカン分解物の摂取群
では、飼料効率がコントロ−ル群と変わらないにも拘わ
らず、コントロ−ル群に比べ脂肪組織が約２９％減少し
ており、体脂肪の増加が抑制されていることは明らかで
ある。また、表３から、キシログルカン分解物の摂取群
では、総脂質，総コレステロ−ル，血漿トリグリセリド
値がコントロ−ル群に比べ、それぞれ約１７％，約１４
％，約１５％減少しており、脂質代謝の改善が明らかに
認められる。また、高脂肪食負荷が原因と考えられる脂
肪肝に対しても、キシログルカン分解物の摂取群ではＧ
ＯＴ値がコントロ−ル群に比べ約３４％減少し、その効
果は明らかである。From Table 2, it can be seen that in the ingested group of xyloglucan degradation product, although the feed efficiency was the same as that in the control group, the adipose tissue was reduced by about 29% as compared with the control group. It is clear that the increase of the is suppressed. Also, from Table 3, in the group ingesting the xyloglucan degradation product, the total lipid, total cholesterol, and plasma triglyceride levels were about 17% and about 14%, respectively, as compared with the control group.
%, About 15% decrease, clearly improving lipid metabolism. In addition, even for fatty liver, which is considered to be caused by a high-fat diet load, G
The OT value is reduced by about 34% as compared with the control group, and the effect is clear.
【００２６】一方、摘出した肝臓から肝脂質について調
べた。On the other hand, liver lipid was examined from the removed liver.
【００２７】摘出した肝臓を氷冷しながらホモジナイズ
した後その０．５ｇを取り、メタノール５ｍｌとクロロ
ホルム１０ｍｌを加え攪拌後３０００ｒｐｍで１０分遠
心分離し、その上澄液を取る。残渣はクロロホルム／メ
タノール（２：１, v/v ）で攪拌し、上澄液を回収し
て、先の上澄液と合わせる。この上澄液２０ｍｌに０．
０４％塩化カルシウム溶液４ｍｌを加え、１分間振とう
した後遠心分離（３０００ｒｐｍ，１０分）して下層を
洗浄液〔クロロホルム／メタノール（２：１）１２容に
０．０４％塩化カルシウム溶液３容を加え、１分間振と
う後２層に分離した上澄液〕４ｍｌで３回洗浄した。こ
の洗浄した下層液を三角フラスコに移し、４０℃で蒸発
乾固した後、更に、減圧下で９時間乾燥した。重量を測
定して、肝臓ｇ当たりの総脂質値を求めた。The excised liver was homogenized while cooling with ice, 0.5 g of the homogenized mixture was taken, 5 ml of methanol and 10 ml of chloroform were added, and the mixture was stirred and centrifuged at 3000 rpm for 10 minutes to obtain a supernatant. The residue is stirred with chloroform / methanol (2: 1, v / v), the supernatant is recovered and combined with the previous supernatant. 20 ml of this supernatant was added to 0.
After adding 4 ml of 04% calcium chloride solution and shaking for 1 minute, centrifugation (3000 rpm, 10 minutes) was performed and the lower layer was washed with 3 volumes of 0.04% calcium chloride solution in 12 volumes of chloroform / methanol (2: 1). In addition, the mixture was shaken for 1 minute and then separated into two layers, and the supernatant was washed 3 times with 4 ml. The washed lower layer liquid was transferred to an Erlenmeyer flask, evaporated to dryness at 40 ° C., and further dried under reduced pressure for 9 hours. The weight was measured to determine the total lipid value per g of liver.
【００２８】また、総コレステロール，リン脂質，トリ
グリセリドの測定は次の前処理後行った。The total cholesterol, phospholipids and triglycerides were measured after the following pretreatment.
【００２９】上記のホモジナイズした肝臓０．１ｇを取
り、メタノール１．７ｍｌとクロロホルム３．３ｍｌを
加え攪拌した後遠心分離（３０００ｒｐｍ，１０分）し
た。その上澄液に水１ｍｌを加え、振とうした後遠心分
離（３０００ｒｐｍ，１０分）し、下層をクロロホルム
（２ｍｌ），メタノール（４８ｍｌ）および水（４７ｍ
ｌ）の混合液０．２ｍｌで洗浄した。0.1 g of the above homogenized liver was taken, 1.7 ml of methanol and 3.3 ml of chloroform were added, and the mixture was stirred and then centrifuged (3000 rpm, 10 minutes). Water (1 ml) was added to the supernatant, and the mixture was shaken and then centrifuged (3000 rpm, 10 minutes), and the lower layer was chloroform (2 ml), methanol (48 ml) and water (47 m).
It was washed with 0.2 ml of the mixed solution of l).
【００３０】総コレステロール値はコレステロールＥ−
テストワコー（和光純薬工業製）を用いて、リン脂質値
はリン脂質Ｂ−テストワコー（和光純薬工業製）を用い
て、また、トリグリセリド値はトリグリセリドＧ−テス
トワコー（和光純薬工業製）を用いて測定し求めた。そ
の結果を表４に示す。The total cholesterol value is cholesterol E-
Using Test Wako (manufactured by Wako Pure Chemical Industries), phospholipid value is phospholipid B-Test Wako (manufactured by Wako Pure Chemical Industries), and triglyceride value is triglyceride G-Test Wako (manufactured by Wako Pure Chemical Industries). ) Was used for measurement. The results are shown in Table 4.
【００３１】[0031]
【表４】 ＊ｐ＜０．０５；＊＊ｐ＜０．０１；＊＊＊ｐ＜０．０
０１[Table 4] * P <0.05; *** p <0.01; *** p <0.0
01
【００３２】表４から、キシログルカン分解物の摂取群
では、肝臓脂質の総脂質，総コレステロ−ル，トリグリ
セリドおよびリン脂質の値が全て、コントロ−ル群に比
べ、有意に低下していた。From Table 4, the values of total lipids, total cholesterol, triglycerides and phospholipids in the liver lipids were all significantly lower in the group ingesting the xyloglucan degradation product as compared with the control group.
【００３３】本発明の有効成分であるキシログルカン分
解物の投与量および投与方法は、例えば、１回０．５〜
１５ｇを１日１〜３回経口投与することが挙げられる。
キシログルカン分解物は、製剤用担体と混合して調整し
た製剤の形で投与することもできるが、種々の食品に添
加して食品の形で投与することもできる。殊に、ダイエ
タリ−食品に添加して、良質のものを得ることができ
る。例えば、菓子類，スナック類，パン類，麺類に製造
上の困難さを伴うことなく含有させることができる。ま
た、従来添加が困難であった飲料，ス−プ類，冷菓，デ
ザ−ト食品などの液状，ゼリ−状食品にも含有させるこ
とができる。The dosage and method of administration of the xyloglucan degradation product, which is the active ingredient of the present invention, are, for example, 0.5 to once.
Oral administration of 15 g once to three times a day can be mentioned.
The xyloglucan degradation product can be administered in the form of a formulation prepared by mixing with a carrier for formulation, or can be added to various foods and administered in the form of food. In particular, it can be added to dietary foods to obtain good quality foods. For example, it can be contained in confectioneries, snacks, breads, noodles without difficulty in production. It can also be contained in liquid or jelly-like foods such as beverages, soups, frozen desserts, and dessert foods, which have been difficult to add in the past.
【００３４】[0034]
【実施例】以下に、製造例および実施例を挙げて本発明
を具体的に説明するが、本発明はこれらに限定されるも
のではない。EXAMPLES The present invention will be specifically described below with reference to production examples and examples, but the present invention is not limited thereto.
【００３５】（製造例１）(Production Example 1)
【００３６】（１）キシログルカンの製造：タマリンド
種子多糖類（大日本製薬株式会社製：商品名「グリロイ
ド３Ｓ」）２．５ｇを２０ｍｌの６０％エタノ−ルに懸
濁し、充分膨潤させた。この懸濁液をスタ−ラ−で攪拌
しながら、水５００ｍｌ中に少しずつ注ぎ、攪拌下７５
℃で１５分間加熱した。これを１００００rpm ×１５分
間遠心分離し、水不溶性の不純物を除去した。上清を１
Ｌのエタノ−ル中に強く攪拌しながら少量ずつ注ぎ、粗
製キシログルカンを沈澱物として得た。これをさらに１
００００rpm ×１５分間遠心分離して脂溶性の不純物を
除去し、得られた沈澱を６７％エタノ−ル，８０％エタ
ノ−ル，１００％エタノ−ル，５０％エタノ−ル／５０
％アセトン，１００％アセトンで順次洗浄し、脱水し
た。これを乾燥させて、精製キシログルカン２．１１ｇ
を得た。(1) Production of xyloglucan: 2.5 g of tamarind seed polysaccharide (manufactured by Dainippon Pharmaceutical Co., Ltd .: trade name "Glyloid 3S") was suspended in 20 ml of 60% ethanol and sufficiently swelled. While stirring this suspension with a stirrer, pour it little by little into 500 ml of water and stir it with stirring.
Heat at 15 ° C for 15 minutes. This was centrifuged at 10,000 rpm for 15 minutes to remove water-insoluble impurities. 1 supernatant
Pour into the ethanol of L little by little with vigorous stirring to obtain crude xyloglucan as a precipitate. This one more
The mixture was centrifuged at 0000 rpm for 15 minutes to remove fat-soluble impurities, and the resulting precipitate was mixed with 67% ethanol, 80% ethanol, 100% ethanol, 50% ethanol / 50.
It was washed with 100% acetone and 100% acetone successively and dehydrated. This is dried to give 2.11 g of purified xyloglucan.
Got
【００３７】（２）キシログルカンオリゴ糖の製造：上
記で調製した精製キシログルカン６００ｍｇをセルラ−
ゼ製剤（株式会社ヤクルト本社製：商品名「セルラーゼ
オノズカ」）２４ｍｇ，０．０２Ｍ酢酸バッファ−１５
０ｍｌ中、ｐＨ４．０，３７℃で７２時間反応させた。
反応液を沸騰湯浴中で３分間加熱して酵素を失活し、AG
501-X8樹脂処理し、ロ−タリ−エバポレ−タ−で濃縮
後、凍結乾燥してキシログルカン分解物５００ｍｇを得
た。(2) Production of xyloglucan oligosaccharide: 600 mg of the purified xyloglucan prepared above was cellularized.
Ze preparation (manufactured by Yakult Honsha Co., Ltd .: trade name "Cellulase Onozuka") 24 mg, 0.02 M acetate buffer-15
The reaction was carried out in 0 ml at pH 4.0 and 37 ° C. for 72 hours.
Heat the reaction in a boiling water bath for 3 minutes to deactivate the enzyme and
It was treated with 501-X8 resin, concentrated with a rotary evaporator, and freeze-dried to obtain 500 mg of a xyloglucan degradation product.
【００３８】本品は以下のような物性を有する。This product has the following physical properties.
【００３９】粘度：キシログルカン分解物を８０℃で１
０分間加熱して得た１０％水溶液を、ブルックフィ−ル
ド粘度計を用いて、２５℃，３０rpm で測定したとこ
ろ、粘度は１０cps 以下であった。 Viscosity : Decomposition product of xyloglucan at 80 ° C.
When a 10% aqueous solution obtained by heating for 0 minutes was measured at 25 ° C. and 30 rpm using a Brookfield viscometer, the viscosity was 10 cps or less.
【００４０】ヨウ素呈色反応：上記水溶液にヨウ化カリ
ウム溶液（０．１Ｍ）を加えて最終ヨウ化カリウム濃度
を０．００２Ｍとするとき、ヨウ素呈色反応を示さな
い。 Iodine color reaction : When a potassium iodide solution (0.1M) is added to the above aqueous solution to bring the final potassium iodide concentration to 0.002M, no iodine color reaction is exhibited.
【００４１】構成糖比：上記水溶液を希釈して１％水溶
液とし、２Ｎ硫酸を等量加えて１００℃で６時間加熱
後、水酸化バリウム水溶液で中和し、脱塩（トヨパック
IC-SP →DEAE→45μm メンブランフィルタ−でろ過）
後、濃縮した。これを高速液体クロマトグラフィ−（カ
ラムShodex Sugar SP0810 →SP0810，溶離液蒸留水，温
度６５℃，流速１．０ｍｌ／分，検出器RI）に付したと
ころ、構成糖比はグルコ−ス：キシロ−ス：ガラクト−
ス＝４：３．５〜２：２〜０であった。 Constituent sugar ratio : The above aqueous solution was diluted to a 1% aqueous solution, an equal amount of 2N sulfuric acid was added, the mixture was heated at 100 ° C. for 6 hours, neutralized with an aqueous barium hydroxide solution, and desalted (Toyopack).
(IC-SP → DEAE → 45 μm membrane filter)
After that, it was concentrated. When this was subjected to high performance liquid chromatography (column Shodex Sugar SP0810 → SP0810, eluent distilled water, temperature 65 ° C, flow rate 1.0 ml / min, detector RI), the constituent sugar ratio was glucose: xylose. : Galacto
S = 4: 3.5-2: 2-0.
【００４２】平均分子量：キシログルカン分解物を高速
液体クロマトグラフィ−（ＨＰＬＣ）（カラムKS800P→
KS805 →KS802 ，溶離液蒸留水，温度６０℃，流速１．
０ｍｌ／分，検出器RI）に付したところ、分子量は６０
０〜３０００の範囲であった。 Average molecular weight : xyloglucan degradation product was analyzed by high performance liquid chromatography (HPLC) (column KS800P →
KS805 → KS802, eluent distilled water, temperature 60 ℃, flow rate 1.
0 ml / min, detector RI), the molecular weight was 60
It was in the range of 0 to 3000.
【００４３】（製造例２） キシログルカン分解物の調
製：タマリンド種子多糖類（大日本製薬株式会社製：商
品名「グリロイド３Ｓ」）１ｋｇを２０Ｌの水に分散
し、セルラ−ゼ製剤（株式会社ヤクルト本社製：商品名
「セルラーゼオノズカ」）１００ｇを添加して３７℃で
７２時間反応させた。反応液は１００℃に昇温して酵素
を失活させた後直ちにろ過して不溶物を除いた。得られ
たろ液をさらに活性炭処理で精製し、減圧濃縮、凍結乾
燥してキシログルカン分解物の粉末６５０ｇを得た。本
品は製造例１（２）で得た製造物とＨＰＬＣで比較した
ところ、同じものであった。(Production Example 2) Preparation of xyloglucan degradation product: 1 kg of tamarind seed polysaccharide (Dainippon Pharmaceutical Co., Ltd .: trade name "Glyloid 3S") was dispersed in 20 L of water to prepare a cellulase preparation (Co., Ltd.). Yakult Honsha Co., Ltd .: trade name "Cellulase Onozuka") (100 g) was added, and the mixture was reacted at 37 ° C for 72 hours. The reaction solution was heated to 100 ° C. to deactivate the enzyme and immediately filtered to remove insoluble materials. The obtained filtrate was further purified by treatment with activated carbon, concentrated under reduced pressure and freeze-dried to obtain 650 g of a powder of a xyloglucan decomposition product. This product was the same when compared with the product obtained in Production Example 1 (2) by HPLC.
【００４４】（実施例１） キシログルカン分解物を含
有する野菜ジュ−ス：野菜ジュ−スに製造例２により得
たキシログルカン分解物の１，３，５重量％をそれぞれ
添加し、キシログルカン分解物を含有する野菜ジュ−ス
を調製した。この調製した野菜ジュ−スをそれぞれ試飲
したところ、無添加の野菜ジュ−スと比べて粘さを感じ
ることもなく、風味，食感をほとんど損なっておらず、
キシログルカン分解物を含有する野菜ジュ−スとして好
ましいものであった。Example 1 Vegetable Juice Containing Decomposed Product of Xyloglucan: 1,3 and 5% by weight of the decomposed product of xyloglucan obtained in Production Example 2 was added to the vegetable juice to give xyloglucan. A vegetable juice containing the decomposed product was prepared. When each of the prepared vegetable juices was tasted, there was no feeling of stickiness as compared with the additive-free vegetable juice, and the flavor and texture were hardly impaired,
It was preferable as a vegetable juice containing a xyloglucan degradation product.
【００４５】（実施例２） キシログルカン分解物を含
有するアイスクリ−ム：下記アイスミルク処方（表５）
により常法で、製造例２により得たキシログルカン分解
物５部を含有するアイスクリ−ムと、対照としてキシロ
グルカン分解物を含有しないアイスクリ−ムとを調製
し、試食した。Example 2 Ice cream containing a xyloglucan degradation product: Ice milk formulation below (Table 5)
Thus, an ice cream containing 5 parts of the xyloglucan degradation product obtained in Production Example 2 and an ice cream not containing the xyloglucan degradation product were prepared and tasted by a conventional method.
【００４６】キシログルカン分解物を含有するアイスク
リ−ムは、含有しないアイスクリ−ムと比べて、風味，
食感ともにほとんど変わらず、キシログルカン分解物を
含有するアイスクリ−ムとして好ましいものであった。The ice cream containing the xyloglucan degradation product has a flavor,
The texture was almost the same, and it was preferable as an ice cream containing a xyloglucan degradation product.
【００４７】[0047]
【表５】 [Table 5]
【００４８】（実施例３） キシログルカン分解物を含
有するス−プ：下記インスタントス−プ処方（表６）に
より、製造例２により得たキシログルカン分解物１０部
を含有する粉末ポタ−ジュス−プと、対照としてキシロ
グルカン分解物を含有しないポタ−ジュス−プとを調製
し、試食した。Example 3 Soup Containing Decomposed Product of Xyloglucan: Powdered potage containing 10 parts of decomposed product of xyloglucan obtained in Production Example 2 according to the following instant spa formulation (Table 6). -, And a control target containing no xyloglucan degradation product were prepared and tasted.
【００４９】キシログルカン分解物を含有するス−プ
は、含有しないス−プと比べて、風味，食感ともにほと
んど変わらず、キシログルカン分解物を含有するス−プ
として好ましいものであった。The soup containing the xyloglucan degradation product showed almost no change in flavor and texture compared to the soup containing no xyloglucan, and was a preferable soup containing the xyloglucan degradation product.
【００５０】[0050]
【表６】 [Table 6]
【００５１】（実施例４） キシログルカン分解物を含
有するデザ−ト食品：下記果汁ゼリ−の処方（表７）に
より常法で、製造例２により得たキシログルカン分解物
４部を含有するゼリ−と、対照としてキシログルカン分
解物を含有しないゼリ−とを調製し、試食した。(Example 4) A dessert food containing a xyloglucan degradation product: 4 parts of the xyloglucan degradation product obtained in Production Example 2 was prepared by a conventional method according to the formulation of the following fruit juice jelly (Table 7). A jelly and a jelly that did not contain a xyloglucan degradation product were prepared and tasted as a control.
【００５２】キシログルカン分解物を含有するゼリ−
は、含有しないゼリ−と比べて、風味，食感ともにほと
んど変わらず、キシログルカン分解物を含有するゼリ−
として好ましいものであった。Jelly containing xyloglucan degradation product
Is almost the same in both flavor and texture as compared with the jelly containing no jelly, and contains the xyloglucan degradation product.
Was preferred.
【００５３】[0053]
【表７】 [Table 7]
【００５４】（実施例５） キシログルカン分解物を含
有する麺：下記即席中華麺の処方（表８）により常法
で、製造例２により得たキシログルカン分解物３部を含
有する麺と、対照としてキシログルカン分解物を含有し
ない麺とを調製し、試食した。(Example 5) Noodles containing xyloglucan degradation product: Noodles containing 3 parts of xyloglucan degradation product obtained in Production Example 2 in a conventional manner according to the following formulation of instant Chinese noodles (Table 8). As a control, noodles containing no xyloglucan degradation product were prepared and tasted.
【００５５】キシログルカン分解物を含有する麺は、含
有しない麺と比べて、風味，食感ともにほとんど変わら
ず、キシログルカン分解物を含有する麺として好ましい
ものであった。The noodles containing the xyloglucan degradation product showed almost no change in flavor and texture compared to the noodles containing no xyloglucan degradation product, and were preferred as noodles containing the xyloglucan degradation product.
【００５６】[0056]
【表８】 [Table 8]
【００５７】[0057]
【発明の効果】本発明の有効成分であるキシログルカン
分解物は、顕著な脂質増加抑制作用，すなわち、体脂肪
の増加抑制作用および血液のみならず肝臓のトリグリセ
リド値，コレステロ−ル値等の上昇抑制作用を有し、ま
た、キシログルカンに比べかなり低粘性であり、これを
食品に添加して摂取しても食感が損なわれず、継続的に
摂取すれば、肥満，高脂血症，脂肪肝などの予防・治療
が可能である。The xyloglucan hydrolyzate, which is the active ingredient of the present invention, has a remarkable inhibitory effect on lipid increase, namely an inhibitory effect on increase in body fat and an increase in not only blood but also triglyceride level and cholesterol level in liver. It has an inhibitory effect, and has a much lower viscosity than xyloglucan, and its texture is not impaired even if it is added to food, and if taken continuously, obesity, hyperlipidemia, fat It is possible to prevent and treat the liver.
Claims (4)
脂質増加抑制剤。1. A lipid increase inhibitor containing a xyloglucan degradation product as an active ingredient.
オリゴ糖である請求項１に記載の脂質増加抑制剤。2. The lipid increase inhibitor according to claim 1, wherein the xyloglucan degradation product is a xyloglucan oligosaccharide.
子多糖類に由来するキシログルカンオリゴ糖である請求
項２に記載の脂質増加抑制剤。3. The lipid increase inhibitor according to claim 2, wherein the xyloglucan oligosaccharide is a xyloglucan oligosaccharide derived from tamarind seed polysaccharide.
有するキシログルカンオリゴ糖である請求項３に記載の
脂質増加抑制剤。 １０％水溶液の２５℃，３０rpm におけるBL型粘度計
による粘度が、１０cps以下． ヨウ素呈色反応を示さない． 構成糖比がグルコース：キシロ−ス：ガラクト−ス＝
４：３．５〜２：２〜０． 平均分子量が６００〜３０００．4. The lipid increase inhibitor according to claim 3, wherein the xyloglucan oligosaccharide is a xyloglucan oligosaccharide having the following physical properties. The viscosity of a 10% aqueous solution at 25 ° C, 30 rpm measured by a BL viscometer is 10 cps or less. No iodine color reaction. The constituent sugar ratio is glucose: xylose: galactose =
4: 3.5-2: 2-0. The average molecular weight is 600 to 3000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32113893A JP3393693B2 (en) | 1993-11-25 | 1993-11-25 | Lipid increase inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32113893A JP3393693B2 (en) | 1993-11-25 | 1993-11-25 | Lipid increase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07147934A true JPH07147934A (en) | 1995-06-13 |
| JP3393693B2 JP3393693B2 (en) | 2003-04-07 |
Family
ID=18129230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP32113893A Expired - Fee Related JP3393693B2 (en) | 1993-11-25 | 1993-11-25 | Lipid increase inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3393693B2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251878B1 (en) * | 1998-07-10 | 2001-06-26 | Board Of Regents, The University Of Texas System | Inhibition of UV-induced immune suppression and interleukin-10 production by cytoprotective tamarind oligosaccharides |
| JP2003339350A (en) * | 2002-05-27 | 2003-12-02 | Toyo Shinyaku:Kk | Diet food |
| JP2003339348A (en) * | 2002-05-27 | 2003-12-02 | Toyo Shinyaku:Kk | Health food |
| WO2006057406A1 (en) | 2004-11-29 | 2006-06-01 | Suntory Limited | Intraoral pungent substance |
| JP2011246413A (en) * | 2010-05-28 | 2011-12-08 | Mitsubishi Rayon Co Ltd | α-GLUCOSIDASE INHIBITOR |
| JP2015078213A (en) * | 2014-12-04 | 2015-04-23 | 三菱レイヨン株式会社 | α-GLYCOSIDASE INHIBITOR |
| JP2021503953A (en) * | 2017-11-22 | 2021-02-15 | テクニスチェ ユニベルシタト ミュンヘン | How to prepare xyloglucan-oligosaccharides |
| WO2022230966A1 (en) * | 2021-04-28 | 2022-11-03 | 住友ファーマフード＆ケミカル株式会社 | Tamarind decomposition product, butyric acid-producing bacteria propagation promoter, composition for intestinal butyric acid production, and tamarind decomposition product production method |
-
1993
- 1993-11-25 JP JP32113893A patent/JP3393693B2/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251878B1 (en) * | 1998-07-10 | 2001-06-26 | Board Of Regents, The University Of Texas System | Inhibition of UV-induced immune suppression and interleukin-10 production by cytoprotective tamarind oligosaccharides |
| JP2003339350A (en) * | 2002-05-27 | 2003-12-02 | Toyo Shinyaku:Kk | Diet food |
| JP2003339348A (en) * | 2002-05-27 | 2003-12-02 | Toyo Shinyaku:Kk | Health food |
| WO2006057406A1 (en) | 2004-11-29 | 2006-06-01 | Suntory Limited | Intraoral pungent substance |
| JP2011246413A (en) * | 2010-05-28 | 2011-12-08 | Mitsubishi Rayon Co Ltd | α-GLUCOSIDASE INHIBITOR |
| JP2015078213A (en) * | 2014-12-04 | 2015-04-23 | 三菱レイヨン株式会社 | α-GLYCOSIDASE INHIBITOR |
| JP2021503953A (en) * | 2017-11-22 | 2021-02-15 | テクニスチェ ユニベルシタト ミュンヘン | How to prepare xyloglucan-oligosaccharides |
| WO2022230966A1 (en) * | 2021-04-28 | 2022-11-03 | 住友ファーマフード＆ケミカル株式会社 | Tamarind decomposition product, butyric acid-producing bacteria propagation promoter, composition for intestinal butyric acid production, and tamarind decomposition product production method |
| JP7203403B1 (en) * | 2021-04-28 | 2023-01-13 | 住友ファーマフード＆ケミカル株式会社 | Tamarind decomposition product, butyric acid-producing bacteria growth promoter, composition for intestinal butyric acid production, and method for producing tamarind decomposition product |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3393693B2 (en) | 2003-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6779287B2 (en) | Steviol glycoside sweetener with improved flavor profile | |
| RU2656390C2 (en) | Compositions and methods for improving rebaudioside m solubility | |
| CN105530960B (en) | The Rebaudiodside A X of sugariness enhancing is provided | |
| CN108289485B (en) | Steviol glycoside blends, compositions, and methods | |
| Mrabet et al. | Date palm fruits as a potential source of functional dietary fiber: A review | |
| CN117752032A (en) | Sweetness and taste improvement of dihydrochalcones on steviol glycosides and mogroside sweeteners | |
| EP2081446B1 (en) | Improved thickener composition for food products | |
| CN114794444A (en) | Stevia extract rich in rebaudioside D, E, N and/or O and preparation method thereof | |
| JP2010254702A (en) | Composition containing viscous fiber and viscosity lowering protein | |
| CN101938911A (en) | Protein-dense micellar casein-based liquid enteral nutritional composition | |
| JPH05255404A (en) | Slightly digestible dextrin | |
| US5268367A (en) | Composition and method for lowering blood level of LDL-cholesterol | |
| JP2013075917A (en) | Food containing glycogen and use thereof | |
| CN110475484B (en) | Stevia plant and application thereof | |
| JPH0632802A (en) | Hardly digestible dextrin | |
| Cui et al. | Dietary fiber: Fulfilling the promise of added-value formulations | |
| JP2753726B2 (en) | Low molecular weight guar gum, method for producing the same, and food and drink containing the same | |
| JP2002241784A (en) | beta GLUCAN-CONTAINING OIL AND FAT COMPOSITION | |
| JP3213648B2 (en) | Method for producing water-soluble polysaccharide | |
| JPH07147934A (en) | Lipid increase inhibitor | |
| JP5013588B2 (en) | Blood lipid improver | |
| ES2536217T3 (en) | Agent to decrease postprandial increase in neutral fats in the blood | |
| EP1616873B1 (en) | Lipid-regulating agent and use thereof | |
| JP4022350B2 (en) | Composition having an inhibitory effect on cholesterol elevation and an inhibitory effect on HDL-cholesterol lowering | |
| JP3523958B2 (en) | Lipid increase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090131 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100131 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110131 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |